TMCnet News

Global Myelodysplastic Syndrome Pipeline Report 2016 - Pipeline Review of 92 Therapeutic Companies - Research and Markets
[June 24, 2016]

Global Myelodysplastic Syndrome Pipeline Report 2016 - Pipeline Review of 92 Therapeutic Companies - Research and Markets


Research and Markets has announced the addition of the "Myelodysplastic Syndrome - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Myelodysplastic Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myelodysplastic Syndrome and special features on late-stage and discontinued projects.

The report enhances decision-making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Myelodysplastic Syndrome Overview
  3. Therapeutics Development
  4. Pipeline Products for Myelodysplastic Syndrome - Overview
  5. Pipeline Products for Myelodysplastic Syndrome - Comarative Analysis
  6. Myelodysplastic Syndrome - Therapeutics under Development by Companies
  7. Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes
  8. Myelodysplastic Syndrome Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Myelodysplastic Syndrome - Products under Development by Companies
  13. Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes
  14. Myelodysplastic Syndrome - Companies Involved in Therapeutics Development
  • 4SC AG
  • Acceleron Pharma, Inc.
  • Actinium Pharmaceuticals, Inc.
  • Aeglea BioTherapeutics, Inc.
  • Agios Pharmaceuticals, Inc.
  • Altor BioScience Corporation
  • Amgen Inc.
  • Apogenix GmbH
  • Arno Therapeutics, Inc.
  • Arog Pharmaceuticals, Inc.
  • Array BioPharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Atara Biotherapeutics, Inc.
  • Bellicum Pharmaceuticals, Inc.
  • Bio-Path Holdings, Inc.
  • BioLineRx, Ltd.
  • BioLite, Inc.
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co., Ltd.
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cantex Pharmaceuticals, Inc.
  • Celator Pharmaceuticals, Inc.
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Cellerant Therapeutics, Inc.
  • Celyad SA
  • Constellation Pharmaceuticals, Inc.
  • Cornerstone Pharmaceuticals, Inc.
  • CrystalGenomics, Inc.
  • CTI (News - Alert) BioPharma Corp.
  • Cyclacel Pharmaceuticals, Inc.
  • Daiichi Sankyo Company, Limited
  • DiNonA Inc.
  • Eisai Co., Ltd.


For more information visit http://www.researchandmarkets.com/research/tqcm9f/myelodysplastic



[ Back To TMCnet.com's Homepage ]